Related Experiment Videos
Chemotherapeutic strategies for renal cell carcinoma
Matthew I Milowsky1, David M Nanus
1Division of Hematology/Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, ST-359, New York, NY 10021, USA.
Abstract:
Metastatic renal cell carcinoma (RCC) is a disease that is highly resistant to systemic chemotherapy. Responses to combination chemotherapy have been reported in patients with collecting duct carcinoma and the sarcomatoid variant of renal cancer. Clinical trials combining chemotherapy with biologic response modifiers have not resulted in significant advances in the treatment of RCC. Patients with advanced local or metastatic RCC should be offered investigational therapeutic options. The identification of novel agents with significantly improved antitumor activity remains a high priority in the treatment of this disease.
Insights
Metastatic renal cell carcinoma (RCC) shows resistance to chemotherapy. New investigational therapies are crucial for advanced cases, as current treatments offer limited progress for this challenging cancer.
Area of Science:
- Oncology
- Urologic Oncology
Background:
- Metastatic renal cell carcinoma (RCC) is notoriously resistant to conventional systemic chemotherapy.
- Limited efficacy has been observed with combination chemotherapy regimens, even in specific subtypes like collecting duct carcinoma and sarcomatoid RCC.
Purpose of the Study:
- To review the current treatment landscape for metastatic renal cell carcinoma.
- To highlight the unmet need for effective therapeutic options in advanced RCC.
Main Methods:
- Review of existing literature on renal cell carcinoma treatment.
- Analysis of clinical trial outcomes for chemotherapy and biologic response modifiers in RCC.
Main Results:
- Chemotherapy resistance is a significant challenge in metastatic RCC.
- Combination chemotherapy has shown minimal benefit, with no substantial advances from combining chemotherapy with biologic response modifiers.
- Investigational therapeutic options are recommended for patients with advanced or metastatic RCC.
Conclusions:
- Novel agents with enhanced antitumor activity are urgently needed for effective metastatic RCC treatment.
- Current treatment strategies for advanced RCC are insufficient, necessitating further research and development of new therapies.